Extended interval dosing of natalizumab: a two-center, 7-year experience.

ABSTRACT:

Background

The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple sclerosis (MS), has been tempered by the risks of progressive multifocal leukoencephalopathy associated with its use, and strategies to minimize those risks are of great interest. Extended interval dosing (EID) has been proposed as a way to maintain the efficacy of natalizumab while reducing exposure to it. We reviewed a cohort of patients who received natalizumab at 6-8-week intervals instead of the typical infusions every 4 weeks with the goal to assess if patients on EID had an increase in clinical relapses.

Methods

This is a retrospective review of all patients with MS treated with natalizumab at two MS centers where patients were offered the opportunity to switch to an EID

SUBMITTER: Bomprezzi R 

PROVIDER: S-EPMC4206618 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature